Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Next Previous
X
Search
Trial Profile

Multicenter phase IV.II Trial, for the administration of capecitabine simultaneous to radiotherapy for local relapse breast cancer patients with negative HER2 [human epidermal growth factor receptor-2] tumours

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Jun 2009 Planned end date changed from 1 Dec 2010 to 1 Jan 2009 as reported by ClinicalTrials.gov.
    • 30 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 May 2009 Trial phase changed from IV to II as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top